Cyclin-dependant kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer

Journal of Cancer Research and Clinical Oncology

Volumn 132, Issue 3, 2006, Pages 163-170

  Schmider Ross, Annette ^a   Pirsig, Olaf ^a   Gottschalk, Elisabeth ^a   Denkert, Carsten ^a   Lichtenegger, Werner ^a   Reles, Angela ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

CIP1 WAF1 (p21); Immunohistochemistry; KIP1 (p27); Ovarian cancer; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; PACLITAXEL; PLATINUM; TUMOR MARKER; CDKN1A PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE DISTRIBUTION; TISSUE SECTION; UNIVARIATE ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; SURVIVAL;

AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 29544433147     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-005-0057-5     Document Type: Article

References (57)

1. Anttila MA, Kosma VM, Hongxiu J, Puolakka J, Juhola M, Saarikoski S, Syrjanen K (1999) p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 79:1870-1878
2. Baekelandt M, Holm R, Trope CG, Nesland JM, Kristensen GB (1999) Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res 5:2848-2853
3. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, Leek R, Morelli L, Leonardi E, Bevilacqua G, Dalla Palma P, Harris AL (1996) p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 74:208-215
4. Barbareschi M, van Tinteren H, Mauri FA, Veronese S, Peterse H, Maisonneuve P, Caffo O, Scaioli M, Doglioni C, Galligioni E, Dalla Palma P, Michalides R (2000) p27(kip1) expression in breast carcinomas: an immunohistochemical study on 512 patients with long-term follow-up. Int J Cancer 89:236-241
5. Bartek J, Lukas J, Bartkova J (1999) Perspective: defects in cell cycle control and cancer. J Pathol 187:95-99
6. Brown JP, Wei W, Sedivy JM (1997) Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277:831-834
7. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227-230
8. Cavalla P, Piva R, Bortolotto S, Grosso R, Cancelli I, Chio A, Schiffer D (1999) p27/kip1 expression in oligodendrogliomas and its possible prognostic role. Acta Neuropathol (Berl) 98:629-634
9. Chen J, Willingham T, Shuford M, Nisen PD (1996) Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. J Clin Invest 97:1983-1988
10. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB (1998) Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 58:114-122
11. Craig C, Wersto R, Kim M, Ohri E, Li Z, Katayose D, Lee SJ, Trepel J, Cowan K, Seth P (1997) A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14 2283-2289
12. Dimanche-Boitrel MT, Micheau O, Hammann A, Haugg M, Eymin B, Chauffert B, Solary E (1998) Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. Int J Cancer 77:796-802
13. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
14. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A (1997) Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381-3385
15. Gartenhaus RB, Wang P, Hoffman M, Janson D, Rai KR (1996) The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. J Mol Med 74:143-147
16. Geisler HE, Geisler JP, Miller GA, Geisler MJ, Wiemann MC, Zhou Z, Crabtree W (2001) p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer 92:781-786
17. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N, Ito H (1997) Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 79:2067-2072
18. Grizzle WE, Manne U, Weiss HL, Jhala N, Talley L (2002) Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1). Int J Cancer 97:403-409
19. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB (1995) Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1021
20. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
21. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816
22. Hurteau JA, Allison BM, Brutkiewicz SA, Goebl MG, Heilman DK, Bigsby RM, Harrington MA (2001) Expression and subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in epithelial ovarian cancer. Gynecol Oncol 83(2):292-298
23. Itami A, Shimada Y, Watanabe G, Imamura M (1999) Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer. Oncology 57:311-317
24. Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli S, Durando A, Arisio R, Diamandis EP (2000) Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Clin Cancer Res 6:3260-3270
25. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234
26. Loden M, Nielsen NH, Roos G, Emdin SO, Landberg G (1999) Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 18:2557-2566
27. Makar AP, Baekelandt M, Trope CG, Kristensen GB (1995) The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56:175-180
28. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G, Giordano A (1999) Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 59:3790-3794
29. Masciullo V, Ferrandina G, Pucci B, Fanfani F, Lovergine S, Palazzo J, Zannoni G, Mancuso S, Scambia G, Giordano A (2000) p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res 6(12):4816-4822
30. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ (1995) p57KIP2, a structurally distinct member of the p2ICIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662
31. Newcomb EW, Sosnow M, Demopoulos RI, Zeleniuch-Jacquotte A, Sorich J, Speyer JL (1999) Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 154:119-125
32. Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K (2002) Increased proliferative activity caused by loss of p21(WAF1/CIP1) expression and its clinical significance in patients with early-stage gastric carcinoma. Cancer 94:2107-2112
33. Nurse P (1994) Ordering S phase and M phase in the cell cycle. Cell 79:547-550
34. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW, Elledge SJ (1995) p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267:1024-1027
35. Plisiecka-Halasa J, Karpinska G, Szymanska T, Ziolkowska I, Madry R, Timorek A, Debniak J, Ulanska M, Jedryka M, Chudecka-Glaz A, Klimek M, Rembiszewska A, Kraszewska E, Dybowski B, Markowska J, Emerich J, Pluzanska A, Goluda M, Rzepka-Gorska I, Urbanski K, Zielinski J, Stelmachow J, Chrabowska M, Kupryjanczyk J (2003) P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 14(7):1078-1085
36. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66
37. Reles A, Schmider A, Press MF, Schonborn I, Friedmann W, Huber-Schumacher S, Strohmeyer T, Lichtenegger W (1996) Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. J Cancer Res Clin Oncol 122:489-494
38. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7:2984-2997
39. Rose SL, Goodheart MJ, DeYoung BR, Smith BJ, Buller RE (2003) p21 expression predicts outcome in p53-null ovarian carcinoma. Clin Cancer Res 9:1028-1032
40. Saegusa M, Machida BD, Okayasu I (2001) Possible associations among expression of p14(ARF), p16(INK4a), p21(WAF1/CIP1), p27(KIP1), and p53 accumulation and the balance of apoptosis and cell proliferation in ovarian carcinomas. Cancer 92:1177-1189
41. Schmider A, Gee C, Friedmann W, Lukas JJ, Press MF, Lichtenegger W, Reles A (2000) p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol 77:237-242
42. Schreiber M, Muller WJ, Singh G, Graham FL (1999) Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene 18:1663-1676
43. Schuyer M, van der Burg ME, Henzen-Logmans SC, Fieret JH, Klijn JG, Look MP, Foekens JA, Stoter G, Berns EM (2001) Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer 85:1359-1367
44. Sgambato A, Ratto C, Faraglia B, Merico M, Ardito R, Schinzari G, Romano G, Cittadini AR (1999) Reduced expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27(Kip1) in human colon cancer. Mol Carcinog 26:172-179
45. Sgambato A, Zhang YJ, Ciaparrone M, Soh JW, Cittadini A, Santella RM, Weinstein IB (1998) Overexpression of p27Kip1 inhibits the growth of both normal and transformed human mammary epithelial cells. Cancer Res 58:3448-3454
46. Sherr CJ (1994) G1 phase progression: cycling on cue [see comments]. Cell 79:551-555
47. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163
48. Singh SP, Lipman J, Goldman H, Ellis FH Jr, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M (1998) Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 58:1730-1735
49. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS (1996) Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2:1204-1210
50. Sui L, Tokuda M, Ohno M, Hatase O, Hando T (1999) The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol 73:202-209
51. Toyoshima H, Hunter T (1994) p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74
52. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM (1998) Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58:542-548
53. Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, Takeda T, Shin E, Takatsuka Y, Kikkawa N, Monden T, Monden M (1997) p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol 107:684-691
54. Wang J, Walsh K (1996) Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science 273:359-361
55. Werness BA, Freedman AN, Piver MS, Romero-Gutierrez M, Petrow E (1999) Prognostic significance of p53 and p21(waf1/cip1) immunoreactivity in epithelial cancers of the ovary. Gynecol Oncol 75:413-418
56. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704
57. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB (1995) High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin Cancer Res 1:1051-1057